Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamotrigine add-on for valproate dose reduction in Japanese premenopausal women with epilepsy
2017-001515-36Phase 4
- Sponsor
- GSK
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lamotrigine and valproic acid in epilepsy, Focal onset seizure and generalized tonic-clonic seizure (GTCS), sponsored by GSK. Primary endpoints: Proportion achieving valproate dose reduction and Percent reduction in daily valproate dose.
02
Drugs
lamotriginevalproic acid
03
Conditions
epilepsyFocal onset seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2017-001515-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001515-36.